CRVS - Company ID 0001626971
The table below shows Corvus Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $15.96M | $11.18M | $8.45M | $7.87M | $7.45M | $5.22M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $3.33M |
| $3.70M |
| $2.12M |
| $2.39M |
| $2.47M |
| $2.03M |
| Operating income | -$19.30M | -$14.88M | -$10.57M | -$10.26M | -$9.92M | -$7.25M |
| Income tax | - | $0.00 | - | - | $0.00 | - |
| Net income | -$17.96M | -$13.69M | -$10.16M | -$8.00M | $15.19M | -$40.22M |
| EPS (diluted) | -$0.19 | -$0.15 | -$0.12 | -$0.10 | -$0.13 | -$0.60 |